Research Use Only. This article discusses compounds and methods studied in preclinical research and laboratory contexts. Products supplied by Omnix Peptides are intended for in vitro research and laboratory use only — not for human consumption, animal consumption outside approved preclinical research, therapeutic application, or clinical use.
KPV — the C-terminal tripeptide Lys-Pro-Val — is a naturally occurring fragment of α-melanocyte-stimulating hormone (α-MSH) that has attracted sustained interest in preclinical research for its immunomodulatory and anti-inflammatory properties. Structurally, it represents the last three amino acids of the thirteen-residue α-MSH sequence and retains a notable share of the parent peptide’s biological activity in research models, despite lacking the classic N-terminal pharmacophore. This article surveys KPV’s sequence and origin, the mechanistic pathways studied in laboratory models, the research contexts in which it has been examined, and practical notes on laboratory handling.
All findings described here derive from in vitro cell culture studies and preclinical animal models; KPV is not approved for human therapeutic use, and the evidence base does not support clinical conclusions. Researchers seeking broader context on the parent molecule class may consult the A-Z Research Peptide Glossary for foundational terminology.
Sequence, Class, and Biological Origin
α-MSH is a tridecapeptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) derived by post-translational processing of pro-opiomelanocortin (POMC). KPV corresponds to positions 11–13 of this sequence. It belongs to the melanocortin peptide family — a class characterised by their origin from POMC and their interactions with melanocortin receptors (MC-Rs), a group of G protein-coupled receptors expressed across immune, neural, and peripheral tissues.[2]
What makes KPV an object of independent research interest is the observation, established across multiple preclinical studies, that the C-terminal tripeptide retains anti-inflammatory activity in the absence of the full α-MSH sequence.[1] Because the canonical “pharmacophore” of α-MSH is generally mapped to the central His-Phe-Arg-Trp core (positions 6–9), the biological activity of the C-terminal fragment suggests additional, receptor-independent or complementary signalling mechanisms operating in research models.
Proposed Mechanisms in Research Models
NF-κB Pathway Modulation
A central mechanistic hypothesis investigated in preclinical research is that KPV, like full-length α-MSH, attenuates nuclear factor kappa B (NF-κB) activation. In inflammatory cell models, α-MSH and related fragments have been shown to preserve IκBα — the inhibitory protein that sequesters NF-κB in the cytoplasm — thereby reducing nuclear translocation and downstream transcription of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α.[3] Research in human keratinocyte (HaCaT) cells reported that KPV modulated the MAPK/NF-κB pathway and reduced IL-1β secretion under particulate matter-induced inflammatory conditions.[6]
Cytokine Profile Effects
Across multiple in vitro systems, α-MSH family peptides have been reported to down-regulate the production of proinflammatory cytokines — including IL-1, IL-6, TNF-α, IL-2, and IFN-γ — while up-regulating the anti-inflammatory cytokine IL-10 in antigen-presenting cell models.[2] Studies examining KPV specifically have observed attenuation of pro-inflammatory cytokine outputs in intestinal epithelial cell lines and immune cell models, with effects shown to depend on cellular uptake pathways (see below).[8]
PepT1-Mediated Cellular Uptake in Intestinal Models
A particularly well-characterised feature of KPV in gastrointestinal research models is its transport via PepT1, the oligopeptide transporter encoded by SLC15A1. PepT1 is constitutively expressed in small intestinal epithelium and is markedly induced in colonic epithelium during experimental intestinal inflammation. Research in Caco-2 and HT29 intestinal epithelial cell lines, as well as murine colitis models, demonstrated that KPV uptake occurs via PepT1, and that this transporter-mediated entry is required for the full anti-inflammatory effect in those systems.[8] This finding has mechanistic implications for understanding how tripeptide fragments might act locally in mucosal environments and informs the design of nanoparticle and oral delivery vehicle studies in the field.
Oxidative Stress and PPARγ Pathway in Hepatic Cell Models
Recent in vitro work in HepG2 hepatocellular cells examined KPV’s effects on oleic acid-induced lipid accumulation and oxidative damage. The study reported that KPV attenuated reactive oxygen species (ROS) generation and suppressed fatty acid synthase (FAS) expression, with effects linked to regulation of the PPARγ pathway — a nuclear receptor central to lipid metabolism research.[4] These observations extend the mechanistic framework for KPV beyond classical cytokine pathways into oxidative stress biology, though the findings remain confined to a single cell-culture model.
Melanocortin Receptor Independence
Unlike full-length α-MSH, which engages MC-1R on monocytes, macrophages, and dendritic cells to initiate canonical anti-inflammatory signalling, KPV lacks the His-Phe-Arg-Trp pharmacophore required for high-affinity MC-R binding.[1] Research has consequently explored whether KPV exerts its effects through receptor-independent intracellular mechanisms or through alternative low-affinity interactions. The PepT1 transporter findings support a model in which intracellular accumulation of the tripeptide — rather than surface receptor engagement — may be the primary driver of activity in mucosal epithelial cells.
Research Applications
Intestinal Inflammation Research
The best-developed research application for KPV to date is in preclinical intestinal inflammation models. The combination of PepT1-mediated uptake in inflamed colon tissue and the ability to attenuate NF-κB-driven cytokine production has made KPV a useful tool peptide in mucosal immunology research.[8] It has been employed in murine colitis models to probe the contribution of luminal peptide transport to epithelial inflammatory signalling. Nanoparticle-encapsulated KPV formulations have also been explored in research settings to improve colonic delivery efficiency.
Skin and Keratinocyte Biology
Research in human HaCaT keratinocytes has used KPV as a probe to study the interplay between environmental oxidative stressors, MAPK signalling, and NF-κB-mediated cytokine production. In one published study, KPV restored cell viability and reduced IL-1β secretion in cells exposed to fine particulate matter (PM10), with effects attributed to suppression of oxidative stress and pathway-level modulation.[6] The parent molecule α-MSH has a well-characterised presence in skin biology, and KPV is examined in this context as a minimal active fragment retaining cutaneous anti-inflammatory activity.[7]
Antimicrobial Research Context
Early work characterising the biological properties of α-MSH fragments reported that KPV, alongside the full-length peptide, exhibited inhibitory activity against Staphylococcus aureus and Candida albicans in laboratory assays.[7] The α-MSH family’s presence in barrier organs — skin and gut — has been interpreted in evolutionary biology as consistent with a role in innate host defence, and KPV’s activity in these assays has informed research into antimicrobial peptide mechanisms. These findings are from in vitro antimicrobial assays and do not constitute evidence for clinical antimicrobial efficacy.
Hepatic Lipid Metabolism Research
The emergence of KPV in hepatic research models represents a newer application area. In vitro experiments using OA-stimulated HepG2 cells have used KPV to interrogate ROS-dependent regulation of lipid synthesis, specifically examining FAS expression and PPARγ pathway involvement.[4] This line of investigation situates KPV alongside other endogenous peptide fragments being studied as molecular tools to dissect metabolic pathway interactions in hepatocellular models.
Neuroimmunomodulatory Research
α-MSH is established in the literature as a neuroimmunomodulatory peptide with activity in both central nervous system and peripheral immune compartments.[3] KPV, as its C-terminal fragment, has been included in research programmes examining the downstream effectors of melanocortin signalling in neuroimmune contexts. Its small size (three residues, molecular weight approximately 342 Da) makes it a tractable probe for structure-activity relationship studies within this compound class. Researchers interested in related melanocortin-system research may find the compound overview within the KLOW blend component review a useful comparative reference, as KPV is one constituent of that formulation.
Structure–Activity Relationship Notes
The observation that KPV retains meaningful anti-inflammatory activity in research models despite lacking the canonical pharmacophore of α-MSH has driven structure-activity relationship (SAR) investigation into the melanocortin peptide class. Studies have compared the potency and mechanistic profile of intact α-MSH, the C-terminal KPV tripeptide, and other fragments, finding that while full-length α-MSH generally shows superior potency in receptor-binding assays, KPV demonstrates a distinct mechanistic profile that may operate partly through receptor-independent intracellular routes.[1][2] The size of the tripeptide also confers relative stability against some proteolytic pathways compared to the full tridecapeptide, a property relevant to research designs requiring sustained exposure in cell culture systems.
Laboratory Handling and Storage
KPV is supplied as a lyophilised (freeze-dried) white to off-white powder, consistent with standard practice for research-grade peptides. As a tripeptide of relatively low molecular weight, KPV is generally soluble in aqueous buffers and sterile water at research-relevant concentrations. The peptide does not contain disulfide bonds or other oxidation-sensitive residues that would necessitate strictly anaerobic handling, though routine precautions against repeated freeze-thaw cycling and prolonged exposure to ambient humidity are standard for any lyophilised peptide.
Long-term storage is recommended at −20 °C in a sealed, desiccated container; working aliquots may be held at 4 °C for short durations once reconstituted. Researchers should consult certificate-of-analysis documentation for lot-specific purity (typically assessed by HPLC) and confirm molecular weight by mass spectrometry data before use. For general principles governing lyophilised peptide handling, the Omnix resource on why peptides ship as powder and how to store them provides a useful framework. Guidance on solvent selection for reconstitution — including the relative merits of bacteriostatic water, sterile water, and saline — is covered in the companion article on reconstitution solvents for research peptides.
Because KPV is a short tripeptide, researchers should be attentive to microgram-scale accuracy when preparing stock solutions; the principles outlined in the Omnix guide to microgram-scale pipetting accuracy are directly applicable to working with low-mass peptide quantities. Full reconstitution calculation methodology is available in the reconstitution math guide for research peptides.
Further compound-specific information, including purity specifications and molecular data, is available on the KPV compound page.
Frequently asked questions
Q: What is KPV and how does it relate to α-MSH?
A: KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment corresponding to positions 11–13 of the thirteen-residue α-melanocyte-stimulating hormone (α-MSH) sequence. It is studied in preclinical research as a biologically active fragment that retains anti-inflammatory properties observed with the full parent peptide, despite lacking the central pharmacophore responsible for high-affinity melanocortin receptor binding.
Q: How is PepT1 relevant to KPV research in intestinal models?
A: PepT1 (encoded by SLC15A1) is a di/tripeptide transporter expressed in small intestinal epithelium and induced in colonic tissue during experimental inflammation. Preclinical research has reported that KPV enters intestinal epithelial and immune cells via PepT1, and that this transporter-mediated uptake is required for the full anti-inflammatory effect observed in murine colitis models and intestinal cell line studies.
Q: Which signalling pathways has KPV been studied in within research models?
A: Published preclinical studies have examined KPV's effects on NF-κB activation, MAPK pathway signalling, PPARγ-mediated lipid metabolism, and reactive oxygen species generation. In keratinocyte and intestinal cell models, effects on cytokine outputs — particularly IL-1β and TNF-α — have been linked to suppression of NF-κB nuclear translocation, consistent with mechanisms described for the parent α-MSH peptide.
Q: What cell and animal models have been used to study KPV?
A: Published research has employed human intestinal epithelial cell lines (Caco-2, HT29), human keratinocytes (HaCaT), hepatocellular HepG2 cells, Jurkat T cells, and murine colitis models. Antimicrobial activity studies have used standard in vitro microbiological assays against Staphylococcus aureus and Candida albicans. All findings are preclinical and in vitro or animal-model-derived.
Q: How should KPV be stored in a laboratory setting?
A: KPV is supplied as a lyophilised powder and is typically stored long-term at −20 °C in a sealed, desiccated container to prevent moisture uptake and degradation. Reconstituted working solutions are generally held at 4 °C for short periods. Repeated freeze-thaw cycling should be minimised by preparing single-use aliquots prior to initial freezing.
Q: Does KPV require melanocortin receptor binding to exert its effects in research models?
A: Evidence from preclinical research suggests that KPV may act via receptor-independent or partially receptor-independent mechanisms in at least some model systems. Because it lacks the His-Phe-Arg-Trp pharmacophore required for high-affinity MC-R engagement, researchers have investigated intracellular accumulation via transporters such as PepT1 as an alternative route by which the tripeptide influences inflammatory signalling pathways.
References
- Brzoska T, Böhm M, Lügering A, Loser K, Luger TA “Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore”. Adv Exp Med Biol 2010;681:107-16. PMID: 21222263 | DOI: 10.1007/978-1-4419-6354-3_8
- Luger TA, Scholzen TE, Brzoska T, Böhm M “New insights into the functions of alpha-MSH and related peptides in the immune system”. Ann N Y Acad Sci 2003;994:133-40. PMID: 12851308 | DOI: 10.1111/j.1749-6632.2003.tb03172.x
- Ichiyama T, Sato S, Okada K, Catania A, Lipton JM “The neuroimmunomodulatory peptide alpha-MSH”. Ann N Y Acad Sci 2000;917:221-6. PMID: 11268347 | DOI: 10.1111/j.1749-6632.2000.tb05386.x
- Lee JY, Lee J, Jung WK, Je JY, Lee SJ “Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells”. Cytotechnology 2026;78(3):98. PMID: 42064835 | DOI: 10.1007/s10616-026-00967-z
- Zeng K, Zhu Y, Han Z, Xiong S, Zhao Y, Xiao Z, Xie Y, Jin S et al. “NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development”. Cell Death Differ 2026;33(2):343-357. PMID: 40935835 | DOI: 10.1038/s41418-025-01578-5
- Sung J, Ju SY, Park S, Jung WK, Je JY, Lee SJ “Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway”. Tissue Cell 2025;95:102837. PMID: 40073467 | DOI: 10.1016/j.tice.2025.102837
- Catania A, Cutuli M, Garofalo L, Carlin A, Airaghi L, Barcellini W, Lipton JM “The neuropeptide alpha-MSH in host defense”. Ann N Y Acad Sci 2000;917:227-31. PMID: 11268348 | DOI: 10.1111/j.1749-6632.2000.tb05387.x
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation”. Gastroenterology 2008;134(1):166-78. PMID: 18061177 | DOI: 10.1053/j.gastro.2007.10.026
Important Notice — Research Use Only
All compounds discussed in this article are described exclusively in the context of laboratory research and preclinical study. Products supplied by Omnix Peptides are intended for in vitro research and laboratory use only. They are not for human consumption, are not for animal consumption outside of approved preclinical animal research, are not intended to diagnose, treat, cure, or prevent any disease, and have not been approved by the FDA for any therapeutic application.
This article makes no claims regarding efficacy, safety, or appropriateness of these compounds for any application outside controlled research settings. Researchers using these compounds are responsible for compliance with all applicable laws, regulations, and institutional review requirements. Information in this article does not constitute medical, veterinary, or scientific advice for any application outside controlled research settings.